Dtsch Med Wochenschr 2012; 137(05): 206-209
DOI: 10.1055/s-0031-1298837
Rheumatologie | Commentary
Rheumatologie
© Georg Thieme Verlag KG Stuttgart · New York

Rheumatoide Arthritis – Remission im Fokus einer zielorientierten Therapie

Rheumatoid arthritis – target-oriented treatment focussing remission
C. Fiehn
1   ACURA-Rheumazentrum Baden-Baden
› Author Affiliations
Further Information

Publication History

Publication Date:
25 January 2012 (online)

    Permissions and Reprints

Schlüsselwörter

rheumatoide Arthritis - Definition der Remission - „treat to target“

Keywords

rheumatoid arthritis - definition of remission - treat to target
 

  • Literatur

  • 1 Bakker MF, Jacobs JW, Welsing PM et al. Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 2011; 70: 1099-1103
    CrossrefGoogle Scholar
  • 2 Crowson CS, Matteson EL, Myasoedova E et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63: 633-639
    CrossrefPubMedGoogle Scholar
  • 3 Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70: 404-413
    CrossrefPubMedGoogle Scholar
  • 4 Fiehn C. Rheumatoide Arthritis: Meilensteine für Klassifikation und Therapie. Dtsch Med Wochenschr 2011; 136: 203-205
    Article in Thieme ConnectGoogle Scholar
  • 5 Fransen J, Creemers MC, van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology 2004; 43: 1252-1255
    CrossrefGoogle Scholar
  • 6 Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-3390
    CrossrefPubMedGoogle Scholar
  • 7 Kalden JR, Burkhardt H, Buss B et al. Strategien zur verbesserten Versorgung von Menschen mit der Volkskrankheit „Rheuma“ am Beispiel der rheumatoiden Arthritis. Z Rheumatol 2011; 70: 641-50
    CrossrefGoogle Scholar
  • 8 Makinen H, Kautiainen H, Hannonen P et al. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?. Ann Rheum Dis 2005; 64: 1410-1413
    CrossrefGoogle Scholar
  • 9 Prevoo ML, van 't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48
    CrossrefPubMedGoogle Scholar
  • 10 Rezaei H, Saevarsdottir S, Forslind K et al. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis 2011; doi DOI: 10.1136/annrheumdis-2011-200038.
    Google Scholar
  • 11 Rotar Z, Praprotnik S, Tomsic M. Clinical contrasts with the American College of Rheumatology/European League Against Rheumatism provisional definitions of remission in rheumatoid arthritis for clinical trials: Comment on the article by Felson et al. Arthritis Rheum 2011; 63: 3642-3643
    Google Scholar
  • 12 Schuch F, Kern P, Kreher G et al. Das Curriculum „Rheumatologische Fachassistenz DGRH-BDRh“ als Weg der Professionalisierung medizinischer Assistenzberufe. Konzept und Ergebnisse einer Evaluation. Z Rheumatol 2011; 70: 670-677
    CrossrefGoogle Scholar
  • 13 Smolen JS, Han C, Heijde DM van der et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009; 68: 823-827
    CrossrefGoogle Scholar
  • 14 Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-975
    Google Scholar
  • 15 Sokka T, Hetland ML, Makinen H et al. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 2008; 58: 2642-2651
    CrossrefGoogle Scholar
  • 16 Gestel AM van, Prevoo ML, Hof MA van t et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40
    CrossrefGoogle Scholar
  • 17 Vermeer M, Kuper HH, Hoekstra M et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011; 63: 2865-2872
    CrossrefGoogle Scholar
  • 18 Verstappen SM, Jacobs JW, Veen MJ van der et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-1449
    CrossrefGoogle Scholar
  • 19 Westlake SL, Colebatch AN, Baird J et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 2011; 50: 518-531
    CrossrefGoogle Scholar